April 22 (Reuters) - Alliqua BioMedical Inc ALQA.O :
* ADYNXX ANNOUNCES MERGER AGREEMENT WITH ALLIQUA BIOMEDICAL
AND
PROVIDES BUSINESS AND CLINICAL UPDATE
* ADYNXX - TO MERGE WITH ALLIQUA BIOMEDICAL AND BECOME A
NASDAQ-LISTED PUBLIC COMPANY IN EARLY 2019
* ADYNXX - ADYNXX SECURITYHOLDERS ARE EXPECTED TO OWN
APPROXIMATELY 86% OF COMBINED COMPANY
* ADYNXX - EXISTING STOCKHOLDERS OF ALLIQUA ARE EXPECTED TO
OWN
APPROXIMATELY 14% OF COMBINED COMPANY
* ADYNXX - ALLIQUA WILL BE RENAMED ADYNXX, INC.
* ADYNXX - WILL BE HEADQUARTERED IN SAN FRANCISCO UNDER
LEADERSHIP
OF ADYNXX'S CURRENT MANAGEMENT TEAM
* ADYNXX - PLANS TO INITIATE TWO PHASE 2 STUDIES OF
BRIVOLIGIDE IN
POSTOPERATIVE PAIN WITH TOPLINE RESULTS EXPECTED IN 2020
Source text for Eikon: ID:nGNX1TyhrB
Further company coverage: ALQA.O
((Briefs@thomsonreuters.com;))